SGO 2020 Annual Meeting

In a small subgroup of patients from the phase 3 ARIEL3 trial, rucaparib improved a number of clinically meaningful end points in addition to progression-free survival. Read More ›

An analysis of patients with recurrent ovarian carcinoma supports the approved starting dose of rucaparib at 600 mg twice daily. Read More ›

Analysis of mutations in homologous recombination deficiency–associated genes in ovarian cancer suggest PARP inhibitors may only benefit a small subset of patients. Read More ›

Although many patients eligible for maintenance therapy do not receive it, research shows that when utilized, maintenance with PARP inhibitors or bevacizumab extends survival. Read More ›

One method used to extrapolate long-term survival data from a phase 3 clinical trial aligned closely with overall survival data from the SEER database, suggesting its utility in informing future treatment and management models when trial data are not yet mature. Read More ›

A real-world, retrospective analysis from community oncology practices reveals a higher clinical and financial burden with PARP inhibitors than reported in clinical trials. Read More ›

Compared with myChoice HRD, percentage of loss of heterozygosity score identifies a significantly smaller proportion of BRCA-mutated tumors. Read More ›

Phase II OVARIO study of niraparib + bevacizumab therapy in advanced ovarian cancer following front-line platinum-based chemotherapy with bevacizumab. Read More ›

In patients with platinum-sensitive recurrent epithelial ovarian cancer, olaparib monotherapy did not improve survival over standard-of-care chemotherapy. Read More ›

After discontinuing treatment with a PARP inhibitor, waiting longer to initiate subsequent therapy was associated with better tolerance to post–PARP inhibitor therapy, with no negative impact on progression-free survival. Read More ›